Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China (Recruiting) - 11 Jun `26D-2570 tablets for nonsegmental vitiligo

D-2570 tablets for nonsegmental vitiligo

Official title: A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo

Status: Recruiting now

Description:

InventisBio Co., Ltd plans to enroll about 160 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 65 may qualify. The study is recruiting at one listed site in China.

Start date: June 11, 2026

Completion date: May 01, 2028

Organizer: InventisBio Co., Ltd

Contact: shilin Sha

Tel.: 1 560 182 667 8

Email: shilin.sha@inventisbio.com

Link: https://clinicaltrials.gov/study/NCT07625891

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference D-2570 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • PTSD in Vitiligo?

    Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...

  • Vitiligo and Pregnancy

    Pregnancy with vitiligo? The good news: vitiligo itself doesn’t make pregnancy unsafe. Most women stay stable (some even improve), though flares can pop up after birth — usually...

  • What are rules for military service entry with vitiligo?

    Military service · Patient guide How do military-service rules for vitiligo differ across countries? There is no global standard. Every country writes its own entry rules, and m...